Ascendis Pharma (ASND) has announced that the FDA has approved YORVIPATH for the treatment of hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone, administered once daily, designed to provide continuous exposure to released PTH over a 24-hour dosing period.
Upon launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program. These services will include support for navigating the treatment journey and financial assistance programs for eligible patients.
Shares of Ascendis Pharma have risen 10% in pre-market trading on Monday.
